RedArc supports ground breaking Group Income Protection

Specialist nurse service provider RedArc is to support Havensrock’s newly launched Group Income Protection solution, the first scheme to provide financial and emotional support to employees who become too ill to work as well as aiming to improve the overall health of all staff.

Through its qualified Nurse Advisers, RedArc will offer valuable support and advice to any employee or family member who falls ‘long term’ sick. The service is tailored specifically to each individual and their illness, whether it is a serious physical or mental condition, disability, trauma, stress or bereavement. This will include extending and enhancing what is available from mainstream services such as the NHS and Social Services.

For the first time with Havensrock, income protection is wellness-enabled. Like more traditional policies, it still provides financial help for members who are too ill to work, but it is also uniquely based on employee wellness, education and engagement to proactively improve workplace health and reduce sickness absence.

Each employee receives a Fitbug Orb, a personal, easy-to-use, wearable movement and sleep tracker to help monitor and meet their individual health and wellbeing goals. Also they will have access to an annual MOT via a mobile interactive health kiosk to record their general health indicators including weight, height, body mass index, body fat index, blood pressure, resting heart rate, hydration and life balance.

RedArc’s managing director Christine Husbands said, “To be part of a new and ground breaking solution for employee protection is very exciting and we look forward to playing our part as we have always prided ourselves on being there for people who really benefit from our services.”


A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Related news

Emergent joins partnership for COVID-19 vaccine development & manufacturing

Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to deploy its...

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...